key: cord-0956277-ia47s8ya
authors: Kayaaslan, Bircan; Kaya Kalem, Ayşe; Asilturk, Dilek; Kaplan, Betul; Dönertas, Gülen; Hasanoglu, Imran; Eser, Fatma; Korkmazer, Ruveyda; Oktay, Zeynep; Ozkocak Turan, Isıl; Erdem, Deniz; Bektas, Hesna; Guner, Rahmet
title: Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients
date: 2022-03-10
journal: Mycoses
DOI: 10.1111/myc.13431
sha: 9266d61612707561d29ccb943ae9ac1a6fa7a87a
doc_id: 956277
cord_uid: ia47s8ya

BACKGROUND: Critically ill COVID‐19 patients have a high risk for the development of candidemia due to being exposed to both well‐defined classical risk factors and COVID‐19‐specific risk factors in ICU. OBJECTIVES: In this study, we investigated the incidence of candidemia in critically COVID‐19 patients, and the independent risk factors for candidemia. PATIENTS/METHODS: COVID‐19 patients hospitalised in ICU during 1‐year period (August 2020 to August 2021) were included. Clinical and laboratory characteristics of all COVID‐19 patients, applied treatments, and invasive procedures that may predispose to candidemia were recorded. RESULTS: Of 1229 COVID‐19 patients, 63 developed candidemia. Candidemia incidence rate was 4.4 episodes per 1000 ICU days. The most common species was Candida albicans (52.3%). Only 37 patients (58.7%) received antifungal therapy. The presence of central venous catheter (OR 4.7, 95% CI 1.8–12.2, p < .005), multifocal candida colonisation (OR 2.7, 95% CI 1.4–5.2, p < .005), a prolonged ICU stay (≥14 days) (OR 1.9, 95% CI 1.08–3–37, p < .05), the absence of chronic lung disease (OR 0.4, 95% CI 0.1–0.9, p < .05) and the absence of corticosteroid use (OR 0.3, 95% CI 0.14–0.52, p < .0001) were significantly associated with candidemia. CONCLUSIONS: Our study filled the knowledge gap in the literature about the impact of COVID‐19‐associated risk factors for the development of candidemia. The classical risk factors for candidemia had a significant effect on candidemia, and contrary to expectations, corticosteroids had a protective effect against the development of candidemia. The results of these studies showing interesting effects of corticosteroids in critically ill COVID‐19 patients should be confirmed by further studies.

great burden on the capacity of the intensive care bed and healthcare services. 3 Approximately 5% of COVID-19 patients experience critical illness requiring follow-up in ICU where the risk of candidemia is high. [3] [4] [5] Additionally, ICU patients with COVID-19 have a higher incidence of candidemia resulting in higher mortality rates compared with those without COVID-19. 6 Therefore, considering candidemia in the early period and the initiation of appropriate treatment in patients at high risk for the development of candidemia is crucial to reducing mortality in severe COIVD-19 patients. [6] [7] [8] [9] In previous studies, some risk factors were defined for the development of candidemia, but almost all were performed in the pre-COVID -19 period. 1, 10, 11 Since severe COVID-19 is a disease with its different characteristics and treatment options, there may be changing or newly added risk factors for the development of candidemia. In this study, we aimed to describe the clinical characteristics of COVID-19 patients with candidemia and risk factors for the development of candidemia in COVID-19 ICU.

This retrospective study was carried out in COVID-19 ICUs of Ankara City Hospital and approved by Ankara City Hospital Ethical Committee 1. The hospital with a capacity of 3810 beds, 696 of which are intensive care beds, served as the reference pandemic centre in Ankara. We planned to collect the data about clinical characteristics of all confirmed COVID-19 cases with and without candidemia followed up in certain ICUs and to determine the risk factors for candidemia. The three COVID-19 ICUs that were visited daily by infectious disease specialists were chosen for the study. All patients over the age of 18 who were hospitalised with a definitive diagnosis of COVID-19 for 1-year period (August 15, 2020, to August 15, 2021) in the ICUs were included in the study. The definitive diagnosis of SARS-CoV-2 infection was made by reverse transcriptase polymerase chain reaction (RT-PCR), which was performed according to the protocol determined by the World Health Organization (WHO) interim guideline. 12 Patients requiring ICU follow-up were considered as severe COVID-19 infection because they met the criteria for severe illness according to the WHO COVID-19 disease severity classification. 13 In our study, the primary outcome was the development of candidemia. All intensive care patients were divided into two groups based on the presence of candidemia as patients with and without candidemia and were compared of demographic characteristics, comorbidities, and the possible risk factors for candidemia. and high dose (250-500-1000 mg). Anakinra and tocilizumab combined under the heading of anti-cytokine therapy. Time from ICU admission to documentation of candidemia was noted. The clinical outcomes (discharge or death), and length of ICU stay were also recorded into the patient's forms.

Isolation of one or more Candida species from at least one blood culture in a patient with findings consistent with infection was defined as candidemia. Blood culture bottles were monitored by BacT/ Alert (bioMerieux) automated blood culture system during the study period. Candida species isolated blood culture, urine, deep tracheal aspirate, or other samples were identified at species level using VitekMS (bioMerieux) device and MALDI-TOF MS method.

Candidemia incidence was calculated as the number of episodes per 1000 ICU days.

Multifocal candida colonisation, candida colonization index, and candida score were recorded in patients' forms. Detection of candida strains at least two cultures obtained from urine, oropharyngeal mucosa, deep tracheal aspirate, and skin (inguinal and/or axillary sites) were defined as multifocal candida colonisation. Candida colonization index (CCI), candida score, and clinical prediction rule were also calculated for each patient. CCI was calculated by the following formula: the ratio of the number of distinct body sites colonised by candida strains /the total number of distinct body site cultures tested. The threshold is 0.5. 11 Total candida score was obtained from the following: multifocal candida colonization (1 point), surgery (1 point), TPN (1 point), and sepsis (2 points). 10 Variables were coded as 0 if they did not exist, and as valid points, if they did. A value of 2.5 was the threshold value for high risk for candidemia. We also used the clinical prediction rule to predict nosocomial invasive candidiasis in patients hospitalised in ICUs. The patients were classified as meeting or not meeting the rule. 1 The rule is defined as follows:

Any systemic antibiotic (days 1-3) or presence of a CVC (days [1] [2] [3] and at least two of the following-TPN (days 1-3), any dialysis (days 1-3), any major surgery (days −7-0), pancreatitis (days −7-0), any use of steroids (days −7-3), or use of other immunosuppressive agents (days −7-0).

An increase of ≥2 points in the Sequential Organ Failure Assessment (SOFA) scoring compared to a baseline condition in a patient with suspicious or definite infection was defined as sepsis. 14 The chronic pulmonary disease category includes chronic obstructive disease, asthma, and interstitial lung disease.

In this study, we recorded previously defined risk factors for candi- Prolonged hospitalisation was considered a potential risk factor for candidemia, and a stay equal to or longer than 14 days in ICU was accepted as a prolonged ICU stay. Comparisons of candidemia groups (absent, exist) in terms of numerical variables were made by using the Mann-Whitney U test due to the violation of the parametric test assumptions. The relationship between candidemia and categorical variables was investigated using the Pearson Chi-square test when the test assumptions were satisfied. Otherwise, Fisher's Exact Test was used. Univariable and multivariate logistic regression analyses were applied to estimate the association between demographical and clinical variables and candidemia. Several independent risk factors such as CVC and use of the broad-spectrum antibiotics caused quasi-complete separation problems due to relatively imbalanced sample size (a rare event). Therefore, univariable penalised logistic regression analysis was applied to those variables. Hence, multiple logistic regression analysis was carried out using penalised maximum likelihood estimation approach with optimal penalisation parameters using the R rms package. A p-value <.05 is considered statistically significant.

All variables which are significant in the univariable logistic regression analysis were considered as candidates for multivariate logistic regression analysis.

Of the 1229 COVID-19 patients followed during the study period, 63 developed candidemia. The candidemia incidence rate was 4.4 episodes per 1000 ICU days, and candidemia was detected after a median of 12 days (IQR 3-16) from the first admission to ICU. The most common species were C. albicans (52.3%) and C. tropicalis (16.9%). Only 37 of candidemia cases (58.7%) had received antifungal therapy. Echinocandins, especially anidulafungin, were the most commonly used antifungal therapy in patients having documented candidemia (Table 1) .

There was no difference in terms of age and gender between patients with and without candidemia (p > .05 for both). At least one comorbidity was present in 82.5% of patients with candidemia and 87.1% of patients without candidemia (p > .05). The two groups were similar in terms of comorbidities, except hypertension and chronic lung disease, which were detected to be higher in patients without candidemia than in those with candidemia (p < .05 for both). Further details are presented in Table 2 .

Compared with the non-candidemia group, invasive procedures were applied at a higher rate in the candidemia group. Mechanical ventilation rate was statistically higher in patients with candidemia (88.9%) than in those without candidemia (48.8%) (p < .001). The patients with candidemia needed CVC use more frequently (95.2% vs. 48.6%, p < .001). There was no history of gastrointestinal instrumentation/surgery and pancreatitis in both candidemia and non-candidemia cases ( Table 2) . ECMO was not used in any of the patients followed up.

We obtained the data upon colonization index, candida score, and clinical prediction rule from all of the patients included in the study. In our routine practice, urine, rectal swab, and blood cultures are taken from all patients admitted to the intensive care unit on the day of admission. If the patient is admitted to the ICU as intubated from another unit, deep tracheal aspirate culture is also taken. The multifocal candida colonisation rate was statistically significantly higher in patients with candidemia (52.4%) than in non-candidemia cases (8.5%) (p < .001). Although the rate of patients with a candidemia score of 3 and above was quite low in both groups, the rate was statistically lower in the non-candidemia group (20.6% vs 10.8%, p < .05). The clinical prediction rule for candidemia was met at a higher rate in candidemia patients (p < .05) ( Table 2) .

Prior nosocomial infection and bacteraemia were more common in the candidemia cases (p < .001 for all), and nearly all cases in the candidemia group received antibiotics during their hospitalisation in ICU before the documentation of candidemia ( Table 2 ). The rates of steroid use at any dose and high doses were lower in candidemia patients (p < .001 for both). The median day of ICU stay was statistically longer in the patients with candidemia (p < .001). The 28-day mortality and overall mortality rates were statistically higher in the candidemia patients. Forty-nine (77.8%) of 63 patients with candidemia died during ICU follow-up (within the first 28-day), 24 of whom had not received any antifungal treatment yet. These patients could not receive any antifungal treatment because they were diagnosed with candidemia after their death.

In the univariate regression analysis, several variables were detected to be significantly associated with the development of candidemia. However, in multivariate regression analysis, the only presence of CVC, multifocal candida colonisation, the absence of chronic lung disease and absence of corticosteroids (at any dose) or high-dose steroid use, and a prolonged ICU stay were significantly associated with candidemia. The results of univariate and multivariate regression analysis are shown in Table 3 .

Severe COVID-19 patients are at high risk for secondary nosocomial infections including candidemia due to mostly requiring ICU followup. Previous studies reported an increased incidence of candidemia in critically ill COVID-19 cases. 6, 8, 9, 15 Current guidelines recommend initiation of empirical antifungal therapy for candida in critically ill patients at high risk of candidemia. 16 The chronic pulmonary disease category includes chronic obstructive disease, asthma and interstitial lung disease. c Other samples contain cerebrospinal fluid, sputum and pleural fluid. This study contributes to our limited knowledge on the epidemiology of candidemia in the COVID ICU by adding some new observational data. Firstly, data of all COVID-19 patients followed in ICU over a 1-year period was included, and the estimated incidence of candidemia was determined. The high incidence of candidemia in our study with 4.4 per 1000 ICU day supported the previous data regarding higher incidence of candidemia reported in COVID-19 studies. 4, 6, 8, 9, 15 Omrani et al reported candidemia incidence as 2.34 episodes per 1000 ICU days in COVID-19 patients. 18 patients. 19 In this study, none of the COVID-19 patients, with and without candidemia, had recent gastrointestinal surgery and an episode of pancreatitis.

The risk factors for the candidemia associated with COVID-19 may be classified as two groups, the well-established classical risk factors, and COVID-19-specific risk factors. Besides classical risk factors, COVID-19 patients are also exposed to specific risk factors such as the use of low-dose or high-dose corticosteroids, anti-cytokine treatment, and ECMO. 20 In this study, we evaluated the risk factors in both groups. In univariate analysis, multiple risk factors were found to be associated with candidemia, but only five of them were found as an independent risk factor in multivariate analysis. Unsurprisingly, our study showed that many of the and TPN were reported as the risk factors associated with the highest risk for invasive Candida infection. 21 Indeed, CVC is a historically well-established risk factor for candidemia, and are frequently needed in COVID-19 patients followed up in ICU. 4, 6, 20, 22 Therefore, defining CVC as a risk factor is an expected result of the study.

Broad-spectrum antibiotics are frequently added to the treatment of the patients whose clinical worsening continues by the physicians following the patients, although it is well known that bacterial co-infections are rare in SARS-CoV-2 infection and that the virus can cause sepsis without any secondary infectious pathogen. 6, 22, 23 Before adding antibiotics to the standard therapy in COVID-19

patients, the risk of superinfection with Candida spp., having high mortality, should be kept in the mind. Previous studies pointed out the impact of broad-spectrum antibiotic on candidemia. 20, 22 In our study it was a possible risk factor candidemia in univariate analysis, however, it had not been detected as an independent risk factor in univariate analysis. Multifocal candida colonisation provides a strong prediction for the development of invasive candida infection. 10, 11, 20 Similarly, multifocal candida colonisation was detected as an independent risk factor for candidemia in our study.

Surprisingly, the absence of chronic lung disease and cortico- anti-cytokine treatment was not found as an independent factor for candidemia. 18 The independent association between the absence of chronic lung disease and candidemia is another unexpected result of our study. Chronic lung disease has been rarely reported as a predisposing factor for candidemia. Omrani et al reported that chronic lung disease was not detected as an independent factor for candidemia in COVID-19 cases. 18 Chronic lung disease has been identified as a predisposing factor for severe COVID-19 causing high mortality. 30, 31 This can be explained by the paradoxical situation that COVID-19 patients with chronic lung disease with a high mortality rate do not have enough time for candidemia to occur.

The present study has a number of limitations. Firstly, the study was performed retrospectively. Therefore, we could not fully record some baseline information of the patients such as the Acute Physiology and Chronic Health Evaluation II (APACHE II) score.

Second, due to the decision to include COVID-19 patients from the only defined ICUs, a relatively small number of patients who were diagnosed candidemia were included in the study.

In conclusion, candidemia is a highly fatal infection in ICU patients. The higher incidence of candidemia in COVID-19 patients 

The authors have no conflicts of interest to declare.

Betul Kaplan: Data curation (supporting). Gulen Donertas: Data curation (supporting). Ruveyda Korkmazer: Data curation (supporting).

Zeynep Oktay: Data curation (supporting). Isıl Ozkocak Turan: Data curation (supporting). Hesna Bektas: Data curation (supporting).

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0001-5225-8319

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness

Candidemia in the intensive care unit

Epidemiology and mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: overall analysis and comparison between non-COVID-19 and COVID-19 cases

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients

A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality

Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic

Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls

Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization

Candida colonization and subsequent infections in critically ill surgical patients

Clinical management of COVID-19. interim guidance

Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans

The third international consensus definitions for sepsis and septic shock

Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids?

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America

Clinical characteristics and risk factors for COVID-19-associated Candidemia

The landscape of candidemia during the COVID-19 pandemic

COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?

Risk factors for invasive candida infection in critically Ill patients: a systematic review and meta-analysis

Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock

Candidemia and severe COVID-19 -which risk factors are modifiable?

Glucocorticoids and invasive fungal infections

Dexamethasone in hospitalized patients with Covid-19

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis

Corticosteroids for pneumonia. Cochrane Database Syst Rev

COVID-19 experience of the major pandemic response center in the capital: results of the pandemic's first month in Turkey

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

How to cite this article

Incidence and risk factors for COVID-19 associated candidemia (CAC) in ICU patients